HomeCompareUDR vs BAX

UDR vs BAX: Dividend Comparison 2026

UDR yields 5.11% · BAX yields 2.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 UDR wins by $29.1K in total portfolio value
10 years
UDR
UDR
● Live price
5.11%
Share price
$33.66
Annual div
$1.72
5Y div CAGR
19.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.7K
Annual income
$6,549.10
Full UDR calculator →
BAX
BAX
● Live price
2.28%
Share price
$15.80
Annual div
$0.36
5Y div CAGR
-27%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.6K
Annual income
$10.26
Full BAX calculator →

Portfolio growth — UDR vs BAX

📍 UDR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodUDRBAX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, UDR + BAX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
UDR pays
BAX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

UDR
Annual income on $10K today (after 15% tax)
$434.34/yr
After 10yr DRIP, annual income (after tax)
$5,566.74/yr
BAX
Annual income on $10K today (after 15% tax)
$193.67/yr
After 10yr DRIP, annual income (after tax)
$8.72/yr
At 15% tax rate, UDR beats the other by $5,558.01/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of UDR + BAX for your $10,000?

UDR: 50%BAX: 50%
100% BAX50/50100% UDR
Portfolio after 10yr
$35.2K
Annual income
$3,279.68/yr
Blended yield
9.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on UDR right now

UDR
Analyst Ratings
18
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$41.10
+22.1% upside vs current
Range: $38.00 — $44.00
Altman Z
0.7
Piotroski
8/9
BAX
Analyst Ratings
15
Buy
20
Hold
1
Sell
Consensus: Hold
Price Target
$19.75
+25.0% upside vs current
Range: $15.00 — $25.00
Altman Z
2.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

UDR buys
9
BAX buys
0
PoliticianChamberTickerTypeAmountDate
Ro Khanna🏢 House$UDR▼ Sell$15,001 - $50,0002025-10-07
Ro Khanna🏢 House$UDR▲ Buy$1,001 - $15,0002025-09-29
Julie Johnson🏢 House$UDR▼ Sell$1,001 - $15,0002025-09-25
Ro Khanna🏢 House$UDR▼ Sell$1,001 - $15,0002025-08-26
Ro Khanna🏢 House$UDR▲ Buy$1,001 - $15,0002025-07-25
Ro Khanna🏢 House$UDR▲ Buy$1,001 - $15,0002023-11-03
Ro Khanna🏢 House$UDR▼ Sell$1,001 - $15,0002023-10-31
Ro Khanna🏢 House$UDR▲ Buy$1,001 - $15,0002023-10-10
Ro Khanna🏢 House$UDR▼ Sell$1,001 - $15,0002023-09-06
Ro Khanna🏢 House$UDR▲ Buy$1,001 - $15,0002023-08-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricUDRBAX
Forward yield5.11%2.28%
Annual dividend / share$1.72$0.36
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR19.3%-27%
Portfolio after 10y$49.7K$20.6K
Annual income after 10y$6,549.10$10.26
Total dividends collected$25.0K$602.00
Payment frequencyquarterlyquarterly
SectorREITHealthcare
Analyst consensusBuyHold
Analyst price target$41.10$19.75

Year-by-year: UDR vs BAX ($10,000, DRIP)

YearUDR PortfolioUDR Income/yrBAX PortfolioBAX Income/yrGap
1← crossover$11,310$609.61$10,866$166.33+$444.00UDR
2$12,870$768.70$11,750$123.31+$1.1KUDR
3$14,746$975.32$12,664$90.97+$2.1KUDR
4$17,024$1,245.96$13,617$66.89+$3.4KUDR
5$19,820$1,603.81$14,619$49.07+$5.2KUDR
6$23,289$2,081.81$15,679$35.94+$7.6KUDR
7$27,647$2,727.39$16,802$26.30+$10.8KUDR
8$33,192$3,609.90$17,998$19.23+$15.2KUDR
9$40,348$4,832.15$19,272$14.05+$21.1KUDR
10$49,721$6,549.10$20,631$10.26+$29.1KUDR

UDR vs BAX: Complete Analysis 2026

UDRREIT

UDR, Inc. (NYSE: UDR), an S&P 500 company, is a leading multifamily real estate investment trust with a demonstrated performance history of delivering superior and dependable returns by successfully managing, buying, selling, developing and redeveloping attractive real estate communities in targeted U.S. markets. As of September 30, 2020, UDR owned or had an ownership position in 51,649 apartment homes including 1,031 homes under development. For over 48 years, UDR has delivered long-term value to shareholders, the best standard of service to Residents and the highest quality experience for Associates.

Full UDR Calculator →

BAXHealthcare

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Full BAX Calculator →
📬

Get this UDR vs BAX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

UDR vs SCHDUDR vs JEPIUDR vs OUDR vs KOUDR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.